Complement Inhibitor Therapeutics Pipeline Developments Research Report 2024
December 05, 2024 10:36 ET
|
Research and Markets
Dublin, Dec. 05, 2024 (GLOBE NEWSWIRE) -- The "Complement Inhibitors - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. The latest comprehensive analysis of the...
Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference
September 23, 2024 09:50 ET
|
Dyadic International, Inc.
JUPITER, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient,...
Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
August 13, 2024 16:05 ET
|
Dyadic International, Inc.
Alternative Proteins Entered into a development and commercialization partnership for the sale of animal-free recombinant albumin products with Proliant Health and BiologicalsEntered into a joint...
Global Plasma Derived Therapies Market to Surpass US$58 Billion by 2028 with Robust Growth in Immunoglobulin and Albumin Segments
June 11, 2024 09:14 ET
|
Research and Markets
Dublin, June 11, 2024 (GLOBE NEWSWIRE) -- The "Plasma Derived Therapies Market (Immunoglobulin, Hemophilia, Specialty, and Albumin): Insights & Forecast (2024-2028)" report has been added to ...
Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
April 30, 2024 16:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...
Dyadic to Attend Industry Events in April
March 27, 2024 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
March 14, 2024 16:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused building...
CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
March 11, 2024 09:57 ET
|
Dyadic International, Inc.
In a release issued under the same headline on Monday, March 11th by Dyadic International, Inc. (NASDAQ: DYAI), please note that the city in the dateline should be JUPITER, Fla. not JUNIPER, Fla. The...
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
March 11, 2024 08:30 ET
|
Dyadic International, Inc.
JUNIPER, Fla., March 11, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Plasma Fractionation Market to reach USD 42.6 billion by 2031, Expanding at a CAGR of 6.7%: Transparency Market Research, Inc.
March 06, 2024 08:00 ET
|
Transparency Market Research
Wilmington, Delaware, United States, March 06, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global plasma fractionation market is estimated to flourish at a CAGR of 6.7% from...